A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
Clinical trial NCT06699914 · COMPLETED
Trial details
- NCT number
- NCT06699914
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-09-06
- Primary completion
- 2023-12-01
- Enrollment
- 438
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.